Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Ornidazole API Manufacturers & Suppliers
1 verified results
All Ornidazole data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 19
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Ornidazole | CAS No: 16773-42-5 | GMP-certified suppliers
A medication that provides systemic antibacterial and antiparasitic activity for the treatment and prevention of protozoal, anaerobic bacterial infections, and related gynecological and genitourinary conditions.
Therapeutic categories
Product Snapshot
- Ornidazole is available in multiple formulation types including film-coated tablets, injectable solutions, and vaginal inserts for intravenous, oral, parenteral, and vaginal administration routes
- Its primary therapeutic use is as an antimicrobial agent targeting anaerobic infections
- Ornidazole is currently in investigational status and not approved by major regulatory authorities
Clinical Overview
Ornidazole’s clinical use has largely been explored in investigational settings. Notably, it has been evaluated in clinical trials focusing on the prevention of infections associated with elective colorectal surgery, suggesting potential utility in surgical prophylaxis. However, an approved specific clinical indication or detailed pharmacodynamic profile is not currently established.
Although the precise mechanism of action for ornidazole is not specified in available data, nitroimidazole derivatives typically exert antimicrobial effects through reduction of the nitro group within anaerobic organisms, generating cytotoxic intermediates that disrupt DNA and cellular function. This mechanism underpins their efficacy against protozoal parasites and anaerobic bacteria.
Key ADME parameters such as absorption, distribution, metabolism, and elimination profiles of ornidazole have not been detailed in this context. Safety and toxicity considerations require careful evaluation; nitroimidazole compounds are generally associated with potential neurotoxicity and gastrointestinal adverse effects, which warrant monitoring during clinical use. Collectively, the safety profile of ornidazole must be considered in relation to its investigational status.
Ornidazole is included in several drug categories related to genitourinary and gynecological antiinfectives, and radiation-sensitizing agents, broadening its scope of investigational applications.
From an API procurement perspective, ensuring the quality of ornidazole is crucial due to its chemical instability potential and sensitivity inherent to nitroimidazole compounds. Sourcing should prioritize manufacturers compliant with Good Manufacturing Practices (GMP) and comprehensive analytical validation to guarantee batch-to-batch consistency and purity, minimizing impurities that may impact therapeutic safety or efficacy.
Identification & chemistry
| Generic name | Ornidazole |
|---|---|
| Molecule type | Small molecule |
| CAS | 16773-42-5 |
| UNII | 62XCK0G93T |
| DrugBank ID | DB13026 |
Formulation & handling
- Ornidazole is a small molecule nitroimidazole suitable for oral, intravenous, parenteral, and vaginal administration forms.
- The compound exhibits moderate water solubility (3.34 g/L) and low lipophilicity (LogP 0.26), supporting formulation in aqueous solutions for injections.
- Handling considerations should include protection from light and moisture to maintain stability, especially in solution dosage forms.
Regulatory status
Ornidazole is a type of Antiprotozoics
Antiprotozoics are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) used to combat protozoan infections. Protozoa are single-celled microorganisms that can cause severe diseases in humans, such as malaria, leishmaniasis, and toxoplasmosis. Antiprotozoic APIs play a crucial role in the development of effective medications to treat these infections.
These APIs work by targeting specific metabolic pathways or enzymes within the protozoan organisms, effectively inhibiting their growth and reproduction. By interrupting essential processes, antiprotozoics can eliminate the protozoa from the body or suppress their activity, allowing the immune system to effectively combat the infection.
Pharmaceutical companies invest significant efforts in research and development to discover and synthesize new antiprotozoic APIs. The goal is to develop highly potent and selective compounds that can effectively eradicate protozoa while minimizing side effects on the human body. This involves rigorous testing and screening of various chemical compounds to identify potential drug candidates with optimal therapeutic properties.
Antiprotozoic APIs are then used as the active ingredients in the formulation of pharmaceutical drugs, such as tablets, capsules, or injectables. These drugs are prescribed by healthcare professionals to patients suffering from protozoan infections. The selection of the appropriate antiprotozoic API depends on the specific protozoan strain and the characteristics of the infection.
In summary, antiprotozoic APIs are essential pharmaceutical ingredients that play a vital role in treating protozoan infections. Their development involves rigorous research and testing to identify potent compounds that can effectively target and eliminate protozoa, leading to improved health outcomes for patients.
Ornidazole (Antiprotozoics), classified under Antiparasitics
Antiparasitics are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that are used to combat parasitic infections in humans and animals. These APIs play a crucial role in the field of medicine and veterinary care by targeting and eliminating various parasites, such as protozoa, helminths, and ectoparasites.
The use of antiparasitics is essential in preventing and treating parasitic diseases, which can cause significant health issues and even be life-threatening. These APIs work by interfering with the parasite's vital biological processes, such as reproduction, metabolism, and survival mechanisms.
Pharmaceutical companies develop and manufacture a wide range of antiparasitic APIs to cater to different parasitic infections. Some common examples of antiparasitics include anthelmintics (used against intestinal worms), antimalarials (used to treat malaria), and ectoparasiticides (used to control external parasites like ticks and fleas).
The development of antiparasitic APIs requires rigorous research, including the identification of suitable targets within the parasite's biology and the formulation of effective chemical compounds. Safety and efficacy are paramount in the manufacturing of antiparasitics, ensuring that they effectively combat the targeted parasites while minimizing adverse effects on the host.
Overall, antiparasitics are vital tools in the fight against parasitic infections, benefiting both human and animal health. Through ongoing research and development, the pharmaceutical industry continues to innovate and improve antiparasitic APIs, contributing to the advancement of healthcare and the well-being of individuals and their animal companions.
Ornidazole API manufacturers & distributors
Compare qualified Ornidazole API suppliers worldwide. We currently have 1 companies offering Ornidazole API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| SETV Global | Producer | India | India | CoA, FDA, GMP | 515 products |
When sending a request, specify which Ornidazole API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Ornidazole API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
